123i-iodobenzamide
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00200447)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 123-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 123i-ibzm
- 123i-ibzm
- 123i-ibzm
- 123i-iodobenzamide
- 123i-iodobenzamide
- 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
- 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide, (r)-isomer
- 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide, (r)-isomer, 125i labeled
- 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide, (s)-isomer, 125i labeled
- 3-iodo-n-(1-ethyl-2-pyrrolidinyl)methyl-2-hydroxy-6-methoxybenzamide
- ibzm
- n-((1-ethyl-2-pyrrolidinyl)methyl)-2-hydroxy-3-iodo-6-methoxybenzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00875407 | N/A | Feb 28, 2009 | Aix-University of Marseille |
| NCT00437177 | Phase 2 | Jan 1, 2007 | Universidad Autonoma de Barcelona |
| NCT00200447 | Phase 2 | Mar 1, 2004 | Molecular NeuroImaging |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aix-University of Marseille | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Molecular NeuroImaging | For profit | 1 | 1 | 1 | 2004 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 1 | 1 | 2007 |
3 organizations
Page 1 / 1